Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesmilifene plus epirubicin and cyclophosphamide versus epirubicin and cyclophosphamide as first-line treatment for metastatic or recurrent breast cancer
2004-001263-22Phase 3Completed
- Sponsor
- YM BioSciences
- Start
- Jan 2005
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in breast cancer comparing Tesmilifene + epirubicin + cyclophosphamide with Epirubicin + cyclophosphamide (2 arms). Primary endpoint: Overall survival. Started Jan 2005; status: completed.
02
Drugs
tesmilifeneepirubicincyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2004-001263-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001263-22.